UB Paderborn / Katalog / Suche / in CDI

Differential microRNA expression in blood in multiple sclerosis

Multiple sclerosis, 2013-12, Vol.19 (14), p.1849-1857

2013

Link zum Volltext

Verfügbarkeit prüfen

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis

Journal of neuroinflammation, 2012-09, Vol.9 (1), p.215-215, Article 719

2012

Link zum Volltext

Verfügbarkeit prüfen

Characterization of the gut bacterial and viral microbiota in latent autoimmune diabetes in adults

Scientific reports, 2024-04, Vol.14 (1), p.8315-8315, Article 8315

2024

Link zum Volltext

Verfügbarkeit prüfen

Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study

Journal of comparative effectiveness research, 2023-02, Vol.12 (2), p.e220187-e220187

2023

Link zum Volltext

Verfügbarkeit prüfen

Blood-brain barrier permeability of normal appearing white matter in relapsing-remitting multiple sclerosis

PloS one, 2013-02, Vol.8 (2), p.e56375-e56375

2013

Link zum Volltext

Verfügbarkeit prüfen

Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis

PloS one, 2015-03, Vol.10 (3), p.e0118830-e0118830

2015

Link zum Volltext

Verfügbarkeit prüfen

Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production

Multiple sclerosis, 2011-05, Vol.17 (5), p.567-577

2011

Link zum Volltext

Verfügbarkeit prüfen

Endogenous and recombinant type I interferons and disease activity in multiple sclerosis

PloS one, 2012-06, Vol.7 (6), p.e35927-e35927

2012

Link zum Volltext

Verfügbarkeit prüfen

Once-Weekly Semaglutide in Adolescents with Obesity

The New England journal of medicine, 2022-12, Vol.387 (24), p.2245-2257

2022

Link zum Volltext

Verfügbarkeit prüfen

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2021-04, Vol.325 (14), p.1414

2021

Link zum Volltext

Verfügbarkeit prüfen

Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg

Obesity (Silver Spring, Md.), 2023-08, Vol.31 (8), p.2139-2149

2023

Link zum Volltext

Verfügbarkeit prüfen

Once-Weekly Subcutaneous Semaglutide 2.4 mg in Adolescents With Overweight or Obesity

Obesity (Silver Spring, Md.), 2022-11, Vol.30, p.12-12

2022

Link zum Volltext

Verfügbarkeit prüfen

Weight Loss Outcomes with Semaglutide 2.4 mg in Moderate or Severe Obesity in STEP 1 and 2

Obesity (Silver Spring, Md.), 2021-12, Vol.29, p.46-46

2021

Link zum Volltext

Verfügbarkeit prüfen

Liraglutide pharmacokinetics and exposure‐response in adolescents with obesity

Pediatric obesity, 2021-10, Vol.16 (10), p.e12799-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract #1003901: Once-Weekly Subcutaneous Semaglutide 2.4 mg Plus Intensive Behavioral Therapy Produces Clinically Meaningful Weight Loss in Adults with Overweight/Obesity Regardless of Baseline Characteristics and Weight History

Endocrine practice, 2021-06, Vol.27 (6), p.S80-S81

2021

Link zum Volltext

Verfügbarkeit prüfen

Adult‐onset type 1 diabetes: Predictors of glycaemic control

Endocrinology, diabetes & metabolism, 2018-10, Vol.1 (4), p.e00038-n/a

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)

Indian journal of endocrinology and metabolism, 2022-03, Vol.26 (Suppl 1), p.S9-S9

2022

Link zum Volltext

Verfügbarkeit prüfen

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)

Journal of the Endocrine Society, 2021-05, Vol.5 (Supplement_1), p.A24-A24

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)

Journal of the Endocrine Society, 2021-05, Vol.5 (Supplement_1), p.A7-A7

2021

Link zum Volltext

Verfügbarkeit prüfen

5 Weight-Loss Maintenance with Once-Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity Reaching Maintenance Dose (STEP 4)

Adipositas - Ursachen, Folgeerkrankungen, Therapie, 2021, Vol.15 (3)

2021

Link zum Volltext

Verfügbarkeit prüfen

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)

Journal of the Endocrine Society, 2021-05, Vol.5 (Supplement_1), p.A63-A64

2021

Link zum Volltext

Verfügbarkeit prüfen

Endogenous Interferon-[beta]-Inducible Gene Expression and Interferon-[beta]-Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis

PloS one, 2015-03, Vol.10 (3)

2015

Link zum Volltext

Verfügbarkeit prüfen

Monitoring urinary orosomucoid in acute inflammation : Observations on urinary excretion of orosomucoid, albumin, α1-microglobulin, and IgG

Clinical chemistry (Baltimore, Md.), 2005-11, Vol.51 (11), p.2052-2058

2005

Link zum Volltext

Verfügbarkeit prüfen

F.73. Expression Profiling of Blood Mononuclear Cells from Patients with Multiple Sclerosis Identifies Differentially Expressed miRNAs and Their mRNA Targets

Clinical immunology (Orlando, Fla.), 2009, Vol.131, p.S113-S113

2009

Link zum Volltext

Verfügbarkeit prüfen

T.71. Effects of Interferon-beta Treatment on T Cell Signature Cytokines and Transcription Factors in Multiple Sclerosis

Clinical immunology (Orlando, Fla.), 2009, Vol.131, p.S70-S71

2009

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Differential microRNA expression in blood in multiple sclerosis

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis

Characterization of the gut bacterial and viral microbiota in latent autoimmune diabetes in adults

Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study

Blood-brain barrier permeability of normal appearing white matter in relapsing-remitting multiple sclerosis

Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis

Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production

Endogenous and recombinant type I interferons and disease activity in multiple sclerosis

Once-Weekly Semaglutide in Adolescents with Obesity

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg

Once-Weekly Subcutaneous Semaglutide 2.4 mg in Adolescents With Overweight or Obesity

Weight Loss Outcomes with Semaglutide 2.4 mg in Moderate or Severe Obesity in STEP 1 and 2

Liraglutide pharmacokinetics and exposure‐response in adolescents with obesity

Abstract #1003901: Once-Weekly Subcutaneous Semaglutide 2.4 mg Plus Intensive Behavioral Therapy Produces Clinically Meaningful Weight Loss in Adults with Overweight/Obesity Regardless of Baseline Characteristics and Weight History

Adult‐onset type 1 diabetes: Predictors of glycaemic control

Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)

5 Weight-Loss Maintenance with Once-Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity Reaching Maintenance Dose (STEP 4)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)

Endogenous Interferon-[beta]-Inducible Gene Expression and Interferon-[beta]-Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis

Monitoring urinary orosomucoid in acute inflammation : Observations on urinary excretion of orosomucoid, albumin, α1-microglobulin, and IgG

F.73. Expression Profiling of Blood Mononuclear Cells from Patients with Multiple Sclerosis Identifies Differentially Expressed miRNAs and Their mRNA Targets

T.71. Effects of Interferon-beta Treatment on T Cell Signature Cytokines and Transcription Factors in Multiple Sclerosis

Suchergebnisse filtern